Arcus Biosciences vs ARS Pharmaceuticals
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $84.3m for ARS Pharmaceuticals (2.9 times as much). Arcus Biosciences grew faster (-4.3% against -5.5%). Arcus Biosciences kept more of each dollar of sales as profit: a net margin of -142.9% against -203.3%.
| Latest fiscal year | Arcus BiosciencesRCUS, 2025 | ARS PharmaceuticalsSPRY, 2025 |
|---|---|---|
| Revenue | $247m | $84.3m |
| Revenue growth | -4.3% | -5.5% |
| Net income | −$353m | −$171m |
| Operating margin | -156.3% | — |
| Net margin | -142.9% | -203.3% |
| Return on equity | -63.3% | -92.3% |
| Free cash flow | −$484m | −$171m |
| Cash | $222m | $41.3m |
| Total debt | $100m | $96.4m |
| Debt to equity | 15.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 601 | 158 |
| Market value | $2.39bn | $298m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 5 sales |